127 related articles for article (PubMed ID: 37060824)
1. Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer.
Liang T; Wu X; Wang L; Ni Z; Fan Y; Wu P; Wang H; Niu Y; Huang H
Pathol Res Pract; 2023 May; 245():154431. PubMed ID: 37060824
[TBL] [Abstract][Full Text] [Related]
2. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
3. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
4. Association Between BRAF
Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnosis of diffuse sclerotic thyroid papillary carcinoma and Hashimoto's thyroiditis using fine-needle aspiration cytology, BRAF
Wang X; Xu F; Gao J; Agyekum EA; Sun H; Zhang G; Li X; Xiang H; Hu S; Qian X
J Clin Ultrasound; 2022 Sep; 50(7):942-950. PubMed ID: 35779272
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
[TBL] [Abstract][Full Text] [Related]
8. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
9. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer.
Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC
Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto's thyroiditis.
Zhang Y; Tian Y
BMC Endocr Disord; 2022 Oct; 22(1):252. PubMed ID: 36266640
[TBL] [Abstract][Full Text] [Related]
11. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
12. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
13. Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
Zhang Q; Liu BJ; Ren WW; He YP; Li XL; Zhao CK; Zhang YF; Yue WW; Zheng JY; Xu HX
Sci Rep; 2017 Jul; 7(1):4899. PubMed ID: 28687736
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues.
Zhang Y; Liu L; Liu Y; Cao N; Wang L; Xing C
Medicine (Baltimore); 2021 Apr; 100(16):e25566. PubMed ID: 33879712
[TBL] [Abstract][Full Text] [Related]
15. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?
Kwak HY; Chae BJ; Eom YH; Hong YR; Seo JB; Lee SH; Song BJ; Jung SS; Bae JS
Int J Clin Oncol; 2015 Jun; 20(3):463-73. PubMed ID: 25312294
[TBL] [Abstract][Full Text] [Related]
16. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
17. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
18. Identifying and analyzing the key genes shared by papillary thyroid carcinoma and Hashimoto's thyroiditis using bioinformatics methods.
Liu TT; Yin DT; Wang N; Li N; Dong G; Peng MF
Front Endocrinol (Lausanne); 2023; 14():1140094. PubMed ID: 37324256
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.
Kang DY; Kim KH; Kim JM; Kim SH; Kim JY; Baik HW; Kim YS
Thyroid; 2007 Nov; 17(11):1031-8. PubMed ID: 17900235
[TBL] [Abstract][Full Text] [Related]
20. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
